Name: Melissa cabral
Email: melissacabral918@yahoo.com
Your Story: I developed c diff colitis in July 2012 following clindamycin for a root canal. The first time I was in the hospital for 8 days. I had recurrent c diff after that until I finally had a fecal transplant. My husband was going to be my donor but he tested positive for c diff as well. My mother ended up being my donor and I’ve been c diff free ever since.
Name: Angie Martin
Your Story: I am a retired healthcare professional, I could not even begin to tell u what I have been thru the last 4 -1/2 yrs….from my FMT’s – to all going on now with my digestive system…IBS/ulcerative colitis, acid reflux and a few polyps that was benign..to having to be very careful with antibiotics. Allergic to quite a few..very slim margin for me for antibiotics..so I don’t get c diff…I dealt with it for almost 3 yrs. A neg result is good news for me…I have been having problems now for the last 6 weeks. But don’t let it get me down. On rocky rd now…I can test neg in stool but yet be positive for it. I have changed my diet..a lot of changes in the last 5 yrs. Please never feel guilty. God made each and everyone of us unique..enjoy life the best we can.
Kudos to this group and the C Diff Foundation Cdifffoundation.org
Name: Rebecca
C.diff.Survivors Name/s: Rebecca
Comment: I have beaten two rounds of c diff! While this was going on, I still managed to work on my college degree, make deans list, and help others. God put it on my heart to say this: when you put your mind to it, you can beat this!
Every day is a new opportunity and miracles happen every day!
Happy Mother’s Day to Women Everywhere!
This year In the United States, Mother’s Day is celebrated on May 14th.
In more than 90 countries Mother’s Day will be celebrated, including many countries where the U.S. based C Diff Foundation is located.
We take this opportunity to celebrate and remember mothers everywhere and the invaluable role that mothers play in families, communities, and business.
The C Diff Foundation is dedicated to educating and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety with support around the globe. There are many avenues connected to C. difficile infections which lead the C Diff Foundation Members and Volunteer Patient Advocates down adjacent roads raising awareness of antibiotic-resistance, antibiotic stewardship programs, Sepsis, and a multitude of general wellness topics around the world.
The C Diff Foundation offers programs enabling healthcare professionals, patients and their families the ability to receive assistance needed during and post-CDI, the ability to receive support care without having to travel during and after experiencing a C. difficile infection, and through the continued support of members and volunteer patient advocates the C Diff Foundation’s mission progresses and grows. Life-saving information reaches villages to cities raising CDI Awareness driving down newly diagnosed CDI’s worldwide.
This week, we will celebrate the success stories of mothers, their mothers, and generations of women, now C.diff. Survivors, living in communities around the world where the C Diff Foundation can be found.
We will also be remembering the thousands of families who have lost their mother to a C. diff. infection and C. diff. infection involvement.
Happy Mother’s Day and good-health wishes are sent to women everywhere!
Clostridium difficile infection is the most common health-care-associated infection in the USA. We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection.
We did a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Participants with signs and symptoms of C difficile infection and a positive diagnostic test result were recruited from 33 centres in the USA and Canada and randomly assigned (1:1) to receive oral ridinilazole (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days. The primary endpoint was achievement of a sustained clinical response, defined as clinical cure at the end of treatment and no recurrence within 30 days, which was used to establish non-inferiority (15% margin) of ridinilazole versus vancomycin. The primary efficacy analysis was done on a modified intention-to-treat population comprising all individuals with C difficile infection confirmed by the presence of free toxin in stool who were randomly assigned to receive one or more doses of the study drug. The study is registered with ClinicalTrials.gov, number NCT02092935.
Between June 26, 2014, and August 31, 2015, 100 patients were recruited; 50 were randomly assigned to receive ridinilazole and 50 to vancomycin. 16 patients did not complete the study, and 11 discontinued treatment early. The primary efficacy analysis included 69 patients (n=36 in the ridinilazole group; n=33 in the vancomycin group). 24 of 36 (66·7%) patients in the ridinilazole group versus 14 of 33 (42·4%) of those in the vancomycin group had a sustained clinical response (treatment difference 21·1%, 90% CI 3·1–39·1, p=0·0004), establishing the non-inferiority of ridinilazole and also showing statistical superiority at the 10% level. Ridinilazole was well tolerated, with an adverse event profile similar to that of vancomycin: 82% (41 of 50) of participants reported adverse events in the ridinilazole group and 80% (40 of 50) in the vancomycin group. There were no adverse events related to ridinilazole that led to discontinuation.
Ridinilazole is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence. Further clinical development is warranted.
Wellcome Trust and Summit Therapeutics.
To read the article in its entirety, please click on the following link:
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30235-9/fulltext
,
,
,
,
,
,
,
,
,
,
,
,
for the
Open access funded by Wellcome Trust
CoDIFy study group†
C. diff. Survivors Network 